Common Stock Valuation Ratios (Price Multiples)
Quarterly Data
Valuation ratios measure the quantity of an asset or flaw (e.g., earnings) associated with ownership of a specified claim (e.g., a share of ownership of the enterprise).
Historical Valuation Ratios (Summary)
Zoetis Inc., historical price multiples (quarterly data)
Based on: 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-10-01), 10-Q (reporting date: 2017-07-02), 10-Q (reporting date: 2017-04-02).
| Valuation ratio | Description | The company |
|---|---|---|
| P/E ratio | The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings. | Zoetis Inc. P/E ratio decreased from Q3 2021 to Q4 2021 and from Q4 2021 to Q1 2022. |
| P/OP ratio | Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit. | Zoetis Inc. P/OP ratio decreased from Q3 2021 to Q4 2021 and from Q4 2021 to Q1 2022. |
| P/S ratio | An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. | Zoetis Inc. P/S ratio decreased from Q3 2021 to Q4 2021 and from Q4 2021 to Q1 2022. |
| P/BV ratio | The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company required rate of return and its actual rate of return. | Zoetis Inc. P/BV ratio decreased from Q3 2021 to Q4 2021 and from Q4 2021 to Q1 2022. |
Price to Earnings (P/E)
Zoetis Inc., historical P/E calculation (quarterly data)
| Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Oct 1, 2017 | Jul 2, 2017 | Apr 2, 2017 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 470,628,655 | 471,970,580 | 473,125,822 | 473,944,193 | 474,766,701 | 475,166,373 | 475,267,819 | 475,144,704 | 474,940,772 | 474,933,945 | 476,299,250 | 477,557,942 | 478,656,189 | 478,771,915 | 480,450,882 | 481,823,803 | 483,865,442 | 485,253,713 | 487,288,245 | 489,111,671 | 490,796,861 | |||||||
| Selected Financial Data (US$) | ||||||||||||||||||||||||||||
| Net income attributable to Zoetis Inc. (in millions) | 595) | 414) | 552) | 512) | 559) | 359) | 479) | 377) | 423) | 384) | 433) | 371) | 312) | 345) | 347) | 384) | 352) | 81) | 298) | 247) | 238) | |||||||
| Earnings per share (EPS)2 | 4.40 | 4.32 | 4.19 | 4.03 | 3.74 | 3.45 | 3.50 | 3.40 | 3.39 | 3.16 | 3.07 | 2.88 | 2.90 | 2.98 | 2.42 | 2.31 | 2.02 | 1.78 | 0.00 | 0.00 | 0.00 | |||||||
| Share price1, 3 | 171.45 | 197.76 | 217.77 | 203.84 | 167.52 | 166.32 | 170.90 | 161.33 | 125.69 | 144.94 | 121.03 | 121.17 | 103.15 | 85.54 | 94.25 | 91.43 | 79.90 | 78.50 | 67.31 | 60.00 | 58.87 | |||||||
| Valuation Ratio | ||||||||||||||||||||||||||||
| P/E ratio4 | 38.92 | 45.82 | 51.98 | 50.61 | 44.83 | 48.25 | 48.84 | 47.41 | 37.05 | 45.89 | 39.46 | 42.08 | 35.57 | 28.68 | 38.90 | 39.51 | 39.53 | 44.09 | — | — | — | |||||||
| Benchmarks | ||||||||||||||||||||||||||||
| P/E Ratio, Competitors5 | ||||||||||||||||||||||||||||
| AbbVie Inc. | 21.64 | 22.07 | 27.34 | 30.62 | 39.63 | 40.17 | 22.60 | 23.92 | 14.70 | 17.82 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Amgen Inc. | 22.23 | 21.05 | 21.91 | 22.56 | 19.20 | 18.82 | 17.25 | 19.97 | 17.70 | 17.07 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Bristol-Myers Squibb Co. | 25.64 | 20.92 | — | — | — | — | — | — | 144.77 | 41.99 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Eli Lilly & Co. | 45.29 | 40.66 | 40.07 | 40.34 | 28.77 | 31.95 | 22.54 | 25.59 | 26.56 | 16.19 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Gilead Sciences Inc. | 17.25 | 12.36 | 11.44 | 16.83 | 277.25 | 641.48 | 59.19 | — | 19.58 | 16.45 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Johnson & Johnson | 23.95 | 20.93 | 23.98 | 25.51 | 28.35 | 28.92 | 22.51 | 25.68 | 23.06 | 25.99 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Merck & Co. Inc. | 15.70 | 14.78 | 28.65 | 34.23 | 28.00 | 26.72 | 17.67 | 19.70 | 19.18 | 20.60 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Pfizer Inc. | 11.11 | 11.76 | 14.03 | 20.05 | 20.15 | 19.62 | 25.36 | 14.99 | 13.04 | 11.63 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 9.15 | 8.37 | 9.96 | 10.38 | 13.27 | 15.09 | 19.91 | 22.27 | 28.35 | 19.86 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Thermo Fisher Scientific Inc. | 28.15 | 27.35 | 29.43 | 24.63 | 23.23 | 27.89 | 38.43 | 44.19 | 35.50 | 33.36 | — | — | — | — | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-10-01), 10-Q (reporting date: 2017-07-02), 10-Q (reporting date: 2017-04-02).
1 Data adjusted for splits and stock dividends.
2 Q1 2022 Calculation
EPS
= (Net income attributable to Zoetis Inc.Q1 2022
+ Net income attributable to Zoetis Inc.Q4 2021
+ Net income attributable to Zoetis Inc.Q3 2021
+ Net income attributable to Zoetis Inc.Q2 2021)
÷ No. shares of common stock outstanding
= (595,000,000 + 414,000,000 + 552,000,000 + 512,000,000)
÷ 470,628,655 = 4.40
3 Closing price as at the filing date of Zoetis Inc. Quarterly or Annual Report.
4 Q1 2022 Calculation
P/E ratio = Share price ÷ EPS
= 171.45 ÷ 4.40 = 38.92
5 Click competitor name to see calculations.
| Valuation ratio | Description | The company |
|---|---|---|
| P/E ratio | The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings. | Zoetis Inc. P/E ratio decreased from Q3 2021 to Q4 2021 and from Q4 2021 to Q1 2022. |
Price to Operating Profit (P/OP)
Zoetis Inc., historical P/OP calculation (quarterly data)
| Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Oct 1, 2017 | Jul 2, 2017 | Apr 2, 2017 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 470,628,655 | 471,970,580 | 473,125,822 | 473,944,193 | 474,766,701 | 475,166,373 | 475,267,819 | 475,144,704 | 474,940,772 | 474,933,945 | 476,299,250 | 477,557,942 | 478,656,189 | 478,771,915 | 480,450,882 | 481,823,803 | 483,865,442 | 485,253,713 | 487,288,245 | 489,111,671 | 490,796,861 | |||||||
| Selected Financial Data (US$) | ||||||||||||||||||||||||||||
| Operating income (in millions) | 787) | 592) | 719) | 703) | 746) | 510) | 659) | 545) | 530) | 482) | 558) | 504) | 423) | 422) | 453) | 479) | 459) | 497) | 457) | 384) | 368) | |||||||
| Operating profit per share2 | 5.95 | 5.85 | 5.66 | 5.52 | 5.18 | 4.72 | 4.66 | 4.45 | 4.37 | 4.14 | 4.00 | 3.77 | 3.71 | 3.79 | 3.93 | 3.93 | 3.71 | 3.52 | 0.00 | 0.00 | 0.00 | |||||||
| Share price1, 3 | 171.45 | 197.76 | 217.77 | 203.84 | 167.52 | 166.32 | 170.90 | 161.33 | 125.69 | 144.94 | 121.03 | 121.17 | 103.15 | 85.54 | 94.25 | 91.43 | 79.90 | 78.50 | 67.31 | 60.00 | 58.87 | |||||||
| Valuation Ratio | ||||||||||||||||||||||||||||
| P/OP ratio4 | 28.81 | 33.82 | 38.47 | 36.90 | 32.33 | 35.22 | 36.65 | 36.24 | 28.78 | 35.00 | 30.23 | 32.11 | 27.78 | 22.59 | 23.98 | 23.28 | 21.51 | 22.33 | — | — | — | |||||||
| Benchmarks | ||||||||||||||||||||||||||||
| P/OP Ratio, Competitors5 | ||||||||||||||||||||||||||||
| AbbVie Inc. | 14.57 | 14.21 | 12.41 | 13.12 | 17.23 | 16.32 | 14.42 | 15.23 | 9.13 | 10.82 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Amgen Inc. | 15.88 | 16.24 | 16.73 | 17.48 | 15.26 | 14.96 | 13.82 | 15.84 | 14.22 | 13.84 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Bristol-Myers Squibb Co. | 20.32 | 19.84 | — | — | — | — | 39.45 | 33.97 | 27.33 | 24.42 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Eli Lilly & Co. | 36.49 | 35.70 | 37.21 | 42.01 | 31.17 | 32.66 | 22.98 | 25.58 | 24.82 | 27.08 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Gilead Sciences Inc. | 10.78 | 7.76 | 7.27 | 8.88 | 18.31 | 19.38 | 29.86 | — | 21.83 | 20.66 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Johnson & Johnson | 21.06 | 18.68 | 18.99 | 20.14 | 21.12 | 21.84 | 19.46 | 19.66 | 18.67 | 19.83 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Merck & Co. Inc. | 14.29 | 15.39 | 30.71 | 38.03 | 30.14 | 23.89 | 16.00 | 17.23 | 15.88 | 17.47 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Pfizer Inc. | 11.49 | 13.30 | 16.37 | 19.83 | 22.85 | 23.12 | 22.27 | 22.17 | 17.42 | 14.36 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 7.98 | 7.55 | 9.32 | 9.65 | 13.32 | 14.82 | 20.36 | 23.98 | 26.60 | 19.01 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Thermo Fisher Scientific Inc. | 21.84 | 21.07 | 23.87 | 19.77 | 18.53 | 22.81 | 31.49 | 36.59 | 28.44 | 26.84 | — | — | — | — | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-10-01), 10-Q (reporting date: 2017-07-02), 10-Q (reporting date: 2017-04-02).
1 Data adjusted for splits and stock dividends.
2 Q1 2022 Calculation
Operating profit per share
= (Operating incomeQ1 2022
+ Operating incomeQ4 2021
+ Operating incomeQ3 2021
+ Operating incomeQ2 2021)
÷ No. shares of common stock outstanding
= (787,000,000 + 592,000,000 + 719,000,000 + 703,000,000)
÷ 470,628,655 = 5.95
3 Closing price as at the filing date of Zoetis Inc. Quarterly or Annual Report.
4 Q1 2022 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= 171.45 ÷ 5.95 = 28.81
5 Click competitor name to see calculations.
| Valuation ratio | Description | The company |
|---|---|---|
| P/OP ratio | Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit. | Zoetis Inc. P/OP ratio decreased from Q3 2021 to Q4 2021 and from Q4 2021 to Q1 2022. |
Price to Sales (P/S)
Zoetis Inc., historical P/S calculation (quarterly data)
| Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Oct 1, 2017 | Jul 2, 2017 | Apr 2, 2017 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 470,628,655 | 471,970,580 | 473,125,822 | 473,944,193 | 474,766,701 | 475,166,373 | 475,267,819 | 475,144,704 | 474,940,772 | 474,933,945 | 476,299,250 | 477,557,942 | 478,656,189 | 478,771,915 | 480,450,882 | 481,823,803 | 483,865,442 | 485,253,713 | 487,288,245 | 489,111,671 | 490,796,861 | |||||||
| Selected Financial Data (US$) | ||||||||||||||||||||||||||||
| Revenue (in millions) | 1,986) | 1,967) | 1,990) | 1,948) | 1,871) | 1,807) | 1,786) | 1,548) | 1,534) | 1,674) | 1,584) | 1,547) | 1,455) | 1,564) | 1,480) | 1,415) | 1,366) | 1,460) | 1,347) | 1,269) | 1,231) | |||||||
| Sales per share2 | 16.77 | 16.48 | 16.10 | 15.64 | 14.77 | 14.05 | 13.76 | 13.34 | 13.35 | 13.18 | 12.91 | 12.66 | 12.36 | 12.17 | 11.91 | 11.60 | 11.25 | 10.94 | 0.00 | 0.00 | 0.00 | |||||||
| Share price1, 3 | 171.45 | 197.76 | 217.77 | 203.84 | 167.52 | 166.32 | 170.90 | 161.33 | 125.69 | 144.94 | 121.03 | 121.17 | 103.15 | 85.54 | 94.25 | 91.43 | 79.90 | 78.50 | 67.31 | 60.00 | 58.87 | |||||||
| Valuation Ratio | ||||||||||||||||||||||||||||
| P/S ratio4 | 10.23 | 12.00 | 13.53 | 13.03 | 11.34 | 11.84 | 12.42 | 12.09 | 9.42 | 11.00 | 9.37 | 9.57 | 8.35 | 7.03 | 7.92 | 7.88 | 7.10 | 7.18 | — | — | — | |||||||
| Benchmarks | ||||||||||||||||||||||||||||
| P/S Ratio, Competitors5 | ||||||||||||||||||||||||||||
| AbbVie Inc. | 4.76 | 4.53 | 3.73 | 3.80 | 4.07 | 4.05 | 4.10 | 4.59 | 3.64 | 4.22 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Amgen Inc. | 5.21 | 5.10 | 5.04 | 5.37 | 5.68 | 5.64 | 5.33 | 6.30 | 5.96 | 6.03 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Bristol-Myers Squibb Co. | 3.41 | 3.16 | 2.85 | 3.44 | 3.28 | 3.16 | 3.66 | 3.97 | 4.45 | 5.52 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Eli Lilly & Co. | 9.47 | 8.01 | 8.62 | 9.16 | 6.88 | 8.06 | 5.41 | 6.26 | 6.36 | 6.03 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Gilead Sciences Inc. | 2.86 | 2.85 | 3.11 | 3.30 | 3.31 | 3.24 | 3.29 | 3.95 | 4.34 | 4.00 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Johnson & Johnson | 5.00 | 4.66 | 4.69 | 5.08 | 5.09 | 5.15 | 4.73 | 4.84 | 4.78 | 4.79 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Merck & Co. Inc. | 4.12 | 3.96 | 4.32 | 4.05 | 4.23 | 3.93 | 4.30 | 4.38 | 4.05 | 4.33 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Pfizer Inc. | 3.00 | 3.18 | 4.04 | 4.78 | 4.84 | 4.50 | 4.71 | 4.69 | 4.21 | 3.66 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 4.40 | 4.20 | 5.14 | 5.20 | 5.78 | 6.24 | 7.62 | 8.31 | 8.10 | 5.34 | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Thermo Fisher Scientific Inc. | 5.20 | 5.39 | 6.45 | 5.54 | 5.13 | 5.52 | 6.58 | 6.24 | 5.08 | 4.83 | — | — | — | — | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-10-01), 10-Q (reporting date: 2017-07-02), 10-Q (reporting date: 2017-04-02).
1 Data adjusted for splits and stock dividends.
2 Q1 2022 Calculation
Sales per share
= (RevenueQ1 2022
+ RevenueQ4 2021
+ RevenueQ3 2021
+ RevenueQ2 2021)
÷ No. shares of common stock outstanding
= (1,986,000,000 + 1,967,000,000 + 1,990,000,000 + 1,948,000,000)
÷ 470,628,655 = 16.77
3 Closing price as at the filing date of Zoetis Inc. Quarterly or Annual Report.
4 Q1 2022 Calculation
P/S ratio = Share price ÷ Sales per share
= 171.45 ÷ 16.77 = 10.23
5 Click competitor name to see calculations.
| Valuation ratio | Description | The company |
|---|---|---|
| P/S ratio | An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. | Zoetis Inc. P/S ratio decreased from Q3 2021 to Q4 2021 and from Q4 2021 to Q1 2022. |
Price to Book Value (P/BV)
Zoetis Inc., historical P/BV calculation (quarterly data)
| Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Oct 1, 2017 | Jul 2, 2017 | Apr 2, 2017 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 470,628,655 | 471,970,580 | 473,125,822 | 473,944,193 | 474,766,701 | 475,166,373 | 475,267,819 | 475,144,704 | 474,940,772 | 474,933,945 | 476,299,250 | 477,557,942 | 478,656,189 | 478,771,915 | 480,450,882 | 481,823,803 | 483,865,442 | 485,253,713 | 487,288,245 | 489,111,671 | 490,796,861 | |||||||
| Selected Financial Data (US$) | ||||||||||||||||||||||||||||
| Total Zoetis Inc. equity (in millions) | 4,658) | 4,543) | 4,679) | 4,350) | 4,089) | 3,769) | 3,602) | 2,982) | 2,753) | 2,708) | 2,678) | 2,411) | 2,317) | 2,185) | 2,118) | 1,970) | 1,960) | 1,770) | 1,989) | 1,715) | 1,609) | |||||||
| Book value per share (BVPS)2 | 9.90 | 9.63 | 9.89 | 9.18 | 8.61 | 7.93 | 7.58 | 6.28 | 5.80 | 5.70 | 5.62 | 5.05 | 4.84 | 4.56 | 4.41 | 4.09 | 4.05 | 3.65 | 4.08 | 3.51 | 3.28 | |||||||
| Share price1, 3 | 171.45 | 197.76 | 217.77 | 203.84 | 167.52 | 166.32 | 170.90 | 161.33 | 125.69 | 144.94 | 121.03 | 121.17 | 103.15 | 85.54 | 94.25 | 91.43 | 79.90 | 78.50 | 67.31 | 60.00 | 58.87 | |||||||
| Valuation Ratio | ||||||||||||||||||||||||||||
| P/BV ratio4 | 17.32 | 20.55 | 22.02 | 22.21 | 19.45 | 20.97 | 22.55 | 25.71 | 21.68 | 25.42 | 21.53 | 24.00 | 21.31 | 18.74 | 21.38 | 22.36 | 19.72 | 21.52 | 16.49 | 17.11 | 17.96 | |||||||
| Benchmarks | ||||||||||||||||||||||||||||
| P/BV Ratio, Competitors5 | ||||||||||||||||||||||||||||
| AbbVie Inc. | 16.59 | 16.53 | 15.20 | 16.23 | 14.91 | 14.18 | 10.93 | 11.31 | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Amgen Inc. | 138.87 | 18.51 | 14.95 | 15.72 | 14.57 | 14.53 | 11.57 | 13.67 | 14.33 | 13.84 | 11.47 | 10.37 | 9.92 | — | — | — | — | — | — | — | — | |||||||
| Bristol-Myers Squibb Co. | 5.07 | 4.07 | 3.48 | 4.15 | 3.73 | 3.55 | 2.87 | 2.82 | 2.77 | 2.80 | 5.30 | 4.63 | 4.91 | — | — | — | — | — | — | — | — | |||||||
| Eli Lilly & Co. | 29.75 | 25.28 | 30.85 | 38.00 | 25.41 | 35.07 | 26.02 | 35.12 | 47.73 | 51.67 | 31.28 | 39.03 | 46.37 | — | — | — | — | — | — | — | — | |||||||
| Gilead Sciences Inc. | 3.91 | 3.65 | 3.94 | 4.41 | 4.40 | 4.33 | 4.30 | 4.79 | 4.40 | 3.93 | 4.02 | 3.58 | 3.83 | — | — | — | — | — | — | — | — | |||||||
| Johnson & Johnson | 6.36 | 5.90 | 6.10 | 6.51 | 6.51 | 6.72 | 5.93 | 6.19 | 6.46 | 6.61 | 5.84 | 5.78 | 6.39 | — | — | — | — | — | — | — | — | |||||||
| Merck & Co. Inc. | 5.44 | 5.05 | 5.76 | 5.73 | 7.30 | 7.46 | 6.97 | 7.47 | 7.43 | 7.83 | 7.87 | 7.82 | 7.31 | — | — | — | — | — | — | — | — | |||||||
| Pfizer Inc. | 3.37 | 3.35 | 3.69 | 3.78 | 3.27 | 2.98 | 3.10 | 3.31 | 3.16 | 3.00 | 3.14 | 3.42 | 3.84 | — | — | — | — | — | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 3.65 | 3.60 | 4.04 | 4.26 | 4.44 | 4.81 | 6.21 | 7.34 | 5.33 | 3.79 | 3.48 | 3.38 | 3.74 | — | — | — | — | — | — | — | — | |||||||
| Thermo Fisher Scientific Inc. | 5.23 | 5.18 | 6.51 | 5.75 | 5.25 | 5.15 | 5.89 | 5.48 | 4.56 | 4.16 | 4.15 | 3.83 | 4.02 | — | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-10-01), 10-Q (reporting date: 2017-07-02), 10-Q (reporting date: 2017-04-02).
1 Data adjusted for splits and stock dividends.
2 Q1 2022 Calculation
BVPS = Total Zoetis Inc. equity ÷ No. shares of common stock outstanding
= 4,658,000,000 ÷ 470,628,655 = 9.90
3 Closing price as at the filing date of Zoetis Inc. Quarterly or Annual Report.
4 Q1 2022 Calculation
P/BV ratio = Share price ÷ BVPS
= 171.45 ÷ 9.90 = 17.32
5 Click competitor name to see calculations.
| Valuation ratio | Description | The company |
|---|---|---|
| P/BV ratio | The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company required rate of return and its actual rate of return. | Zoetis Inc. P/BV ratio decreased from Q3 2021 to Q4 2021 and from Q4 2021 to Q1 2022. |